XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.0700
+0.0100 (+0.94%)
At close: 4:00PM EST

1.0800 +0.01 (0.93%)
After hours: 7:08PM EST

Stock chart is not supported by your current browser
Previous Close1.0600
Open1.0500
Bid1.0200 x 27000
Ask1.0800 x 1800
Day's Range1.0150 - 1.0900
52 Week Range0.7000 - 2.5900
Volume1,244,267
Avg. Volume2,232,516
Market Cap143.829M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.2350
Earnings DateNov 07, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
    Simply Wall St.

    If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • GlobeNewswire

    22nd Century Group Appoints New Director and New Chairman

    Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.

  • GlobeNewswire

    22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

    Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

    Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    22nd Century Group Announces Management Changes

    Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management. “Over the past few months we have made rapid and significant progress in strengthening 22nd Century Group as we execute against our two growth strategies,” commented James W. Cornell, Director & Chairman of the Board of 22nd Century Group.

  • Benzinga

    22nd Century Enters CBD Space With $24M Investment In Panacea

    Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.

  • Business Wire

    Shareholder Alert: Robbins LLP Reminds Investors 22nd Century Group, Inc. (XXII) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins LLP reminds investors that purchasers of 22nd Century Group, Inc. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 18, 2016 and July 31, 2019.

  • GlobeNewswire

    22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

    Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 8-Nov-19 2:00pm GMT

    Q3 2019 22nd Century Group Inc Earnings Call

  • GlobeNewswire

    22nd Century Group Comments on Delay of Reduced Nicotine Rule for Cigarettes

    Williamsville, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, responded today to the FDA’s recent removal of the Tobacco Product Standard for Nicotine Level of Certain Tobacco Products from the Trump administration’s ‘unified agenda.’  The much anticipated Notice of Proposed Rulemaking (NPRM) for the reduced nicotine product standard, which was expected in October, was listed as being “Withdrawn” as of October 23, 2019, on the White House Office of Information and Regulatory Affairs website. The unified agenda was updated with the new information on Wednesday, November 20, 2019, as part of a semiannual review.

  • Business Wire

    22nd Century Group Files 2019 Third Quarter Report

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the Company filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 with the U.S. Securities and Exchange Commission. As previously announced, the Company will provide a business update for investors on an audio only webcast to be held on Friday, November 8, 2019, at 9:00 AM Eastern time. Clifford B. Fleet, President and Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast.

  • GlobeNewswire

    22nd Century Group Announces Webcast to Provide Business Update

    WILLIAMSVILLE, NY -- 22nd Century Group, Inc. (NYSE American:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company will provide a business update for investors via an audio-only webcast on Friday, November 8, 2019, at 9:00 AM Eastern time. Cliff Fleet, Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast. Interested parties are invited to listen to the live event on the 22nd Century website: www.xxiicentury.com/media/2019Q3BusinessUpdate.

  • Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Trump May Ban Flavored E-Cigarettes: Who Wins, Who Loses
    Zacks

    Trump May Ban Flavored E-Cigarettes: Who Wins, Who Loses

    Vaping is a growing trend among youngsters, but Trump's recent threat to ban flavored e-cigarettes raises questions. Will traditional cigarette get back its lost glory?

  • 3 Pot Stocks to Avoid Like the Plague in September
    Motley Fool

    3 Pot Stocks to Avoid Like the Plague in September

    These marijuana stocks are unlikely to have investors seeing green in the near term.

  • Only These 10 Pot Stocks Ended August Higher
    Motley Fool

    Only These 10 Pot Stocks Ended August Higher

    Despite another miserable month for marijuana stocks, these companies managed to buck the trend.

  • 3 Best Marijuana Stocks of August -- Are They Buys Now?
    Motley Fool

    3 Best Marijuana Stocks of August -- Are They Buys Now?

    Most pot stocks performed poorly last month, but not these three highfliers.

  • GuruFocus.com

    22nd Century Group Inc (XXII) President and CEO Clifford B Fleet Bought $190,000 of Shares

    President and CEO of 22nd Century Group Inc (30-Year Financial, Insider Trades) Clifford B Fleet (insider trades) bought 100,000 shares of XXII on 08/27/2019 at an average price of $1.9 a share. Continue reading...

  • Will 22nd Century Group Continue to Surge Higher?
    Zacks

    Will 22nd Century Group Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor 22nd Century Group.

  • 22nd Century Group, Inc. (NYSEMKT:XXII): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.

    22nd Century Group, Inc. (NYSEMKT:XXII): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in 22nd Century Group, Inc. (NYSEMKT:XXII), then you might want to consider its beta (a measure...

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 8-Aug-19 8:00pm GMT

    Q2 2019 22nd Century Group Inc Earnings Call

  • 22nd Century Group Inc (XXII) Q2 2019 Earnings Call Transcript
    Motley Fool

    22nd Century Group Inc (XXII) Q2 2019 Earnings Call Transcript

    XXII earnings call for the period ending June 30, 2019.